Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 PK interaction study of GWP42003-P with stiripentol or valproate in epilepsy
NL-OMON42499Phase 2Withdrawn
- Sponsor
- GW Pharmaceuticals
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol, stiripentol and valproic acid in epilepsy (4 arms), sponsored by GW Pharmaceuticals. Primary endpoints: Stiripentol pharmacokinetics, Valproate pharmacokinetics and 2 more. Planned start Jan 2016; status: withdrawn.
02
Drugs
cannabidiolstiripentolvalproic acid
03
Conditions
epilepsy
Beyond the preview
Go deeper on NL-OMON42499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42499.